In patients with advanced Parkinson disease (PD) who are undergoing long-term treatment with a dopaminergic medication, a down-regulation of striatal dopamine D 2 receptor expression has been demonstrated and interpreted as a consequence of either the disease itself or dopaminergic drug administration.
patients. The same tendency was noted for the caudate nucleus, but was not significant (P=.07). Compared with control subjects, the putaminal raclopride C 11 binding was increased by 21% in off-drug and was normal in ondrug PD patients. Compared with controls, the caudate raclopride C 11 binding was reduced by 23% in on-drug and was normal in off-drug PD patients. Further analysis using statistical parametric mapping showed a significant increase of binding bilaterally in the caudate nucleus and putamen in off-drug compared with on-drug PD patients (P=.002 at cluster level).
Conclusions:
The down-regulation of dopamine D 2 receptors probably relates to the long-term and intermittent administration of dopaminergic treatments rather than to disease progression. This phenomenon is reversed by the complete withdrawal of dopaminergic drugs. Furthermore, an up-regulation of putaminal dopamine D 2 receptors is demonstrated in late-stage PD after dopaminergic drug withdrawal.
Arch Neurol. 2004; 61:1705 -1709 D OPAMINE D 2 RECEPTOR function and availability can be assessed in vivo using positron emission tomography (PET) and raclopride carbon C 11, a dopamine D 2 receptor ligand. 1 In drug-naive or earlystage Parkinson disease (PD) patients, most PET studies using raclopride C 11 show an increased raclopride C 11 binding in the putamen, whereas binding is usually normal in the caudate nucleus. [2] [3] [4] [5] [6] [7] [8] [9] This result has generally been interpreted as a compensatory dopaminergic receptor up-regulation. In advanced PD patients undergoing longterm dopaminergic treatment, a reduction of the striatal raclopride C 11 binding is usually observed in the caudate nucleus and less constantly in the putamen. 3, 7, 8, 10, 11 This modification of dopaminergic D 2 receptor expression may reflect either an effect of disease progression on striatal dopamine D 2 receptor density or a down-regulation of these receptors induced by levodopa and other dopaminergic drugs. 3, 7, 8, 10, 11 To our knowledge, the reversibility of decreased striatal raclopride C 11 binding in advanced PD patients, after complete dopaminergic drug withdrawal, has never been previously assessed because of the inability to completely discontinue dopaminergic medication for any significant period because of the severity of motor symptoms. With the recent advance of deep brain stimulation of the subthalamic nucleus (STN), it is possible, in some patients, to completely interrupt levodopa and dopaminergic agonists after STN stimulation. 12 This allows for the investigation of the respective effects of dopaminergic drug withdrawal and disease progression on striatal dopamine D 2 receptor density and function by using the noninvasive PET raclopride C 11 technique.
The present study compares the striatal raclopride C 11 binding in PD patients undergoing STN stimulation: one group who has completely discontinued dopaminergic drug therapy (off-drug patients) is compared with one group still receiving dopaminergic medications (on-drug patients). Our hypothesis is that if the reduction of striatal raclopride C 11 binding is due to long-term dopaminergic drug intake and not to disease progression, then this down-regulation of dopamine D 2 receptors should be reversed after dopaminergic drug withdrawal.
METHODS

PATIENTS
Twelve severely affected right-handed PD patients were studied. The main clinical characteristics of both groups of patients are presented in Table 1 . The patients fulfilled the United Kingdom Parkinson's Disease Brain Bank criteria for idiopathic PD. 13 All patients had clear and sustained levodopa responsiveness, severe off states, motor fluctuations, and dyskinesias. These patients underwent bilateral surgical implantation of electrodes in the STN (model 3389; Medtronic, Minneapolis, Minn) that were connected to a telemetrically controllable pulse generator (Kinetra; Medtronic), as previously described. 12 At the time of the PET study, patients had been treated by STN stimulation for at least 3 months. The beneficial effects of STN stimulation allowed 5 patients (3 men and 2 women) to completely discontinue all antiparkinsonian medications after STN stimulation (off-drug patients), while 7 patients (3 women and 4 men) continued to receive a long-term dopaminergic treatment, with a mean±SD 66%±10% reduction of the dose (on-drug patients). In the off-drug group of patients, drug withdrawal was achieved within the first month interval between drug withdrawal and PET: mean±SD, 17±6 months (range, 5-29 months). Both groups of patients were similar for age (P=.80), preoperative levodopa responsiveness (assessed by the reduction of the Unified Parkinson's Disease Rating Scale [UPDRS] III motor score) (P=.30), disease duration (P=.70), delay between surgery and PET scanning (P=.60), stimulation variables (P=.80), and improvement of motor complications (assessed by the reduction of the UPDRS IV score) (P=.80). 14 At the time of PET scanning (off medication), the stimulation reduced the UPDRS motor score by a mean±SD of 58%±9% and 76% ± 6% in on-drug and off-drug PD patients, respectively. The UPDRS III motor scores in on-and off-stimulation conditions (off medication) were significantly higher in ondrug vs off-drug patients (PϽ.01).
All patients were off drug on the day of the PET study for at least 12 hours, and the stimulator was switched off 1 hour before scan acquisition.
CONTROL SUBJECTS
Eight right-handed, age-matched, healthy subjects (5 men and 3 women) participated in the study (mean±SD age, 55.7±9.7 years; range, 41-69 years). These subjects had no history of psychiatric or neurological disorders, had a normal physical examination result, and did not receive any medication. The study was performed after approval by the Lyon University Hospitals Ethics Committee. All subjects participated after signing an informed consent form according to the Declaration of Helsinki.
PET PROTOCOL
The PET scans were performed in 3-dimensional mode using a tomograph (Siemens CTI HR+ tomograph; CTI/Siemens, Knoxville, Tenn). The scanning procedure has been described elsewhere. 15 One raclopride C 11 PET scan was obtained for all patients. The stimulator was switched off 1 hour before the PET session. This time frame is consistent with the latency of recurrence of most parkinsonian signs. For assessment of dopamine D 2 receptor binding, 28 sequential scans were obtained over 60 minutes, starting at the time of injection of raclopride C 11 into an antecubital vein over 15 seconds with an automated infusion pump. The mean ± SD injected activity was 0.0059±0.0006, 0.00064±0.0007, and 0.0059±0.0004 C; for on-drug patients, off-drug patients, and controls, respectively.
IMAGE ANALYSIS
Region of Interest Analysis
One elliptical region of interest (ROI) (10ϫ30 mm) was placed along the axis of each putamen, and one circular ROI (10ϫ10 mm) was positioned on each head of the caudate nucleus. These ROIs were placed on the 5 consecutive planes. The nonspecific background activity was averaged from cerebellar elliptical ROIs drawn on 2 consecutive planes. 16 The raclopride C 11 binding potential (binding maximum /Kd) was determined from the distribution volume evaluated using a graphical approach and a tissue input function. 17
Statistical Parametric Mapping Analysis
Image and statistical analyses were performed using an analytical software program MATLAB 5.3 (MathWorks, Natick, *Data are given as mean ± SD. †Levodopa equivalents are 100 mg of L-dopa, 10 mg of bromocriptine, 5 mg of ropinirole hydrochloride, and 1 mg of pergolide mesylate.
‡The range was 6 to 38 months for on-drug PD patients and 3 to 43 months for off-drug PD patients.
§The total score possible was 23. ʈThe total score possible was 108.
(REPRINTED) ARCH NEUROL / VOL 61, NOV 2004 Mass) plus software for statistical parametric mapping (SPM 99; Wellcome Department of Cognitive Neurology, MRC Cyclotron Unit, London). The integrated raclopride C 11 images obtained, as previously described, were normalized to a raclopride C 11 template built on the results of the 8 controls in the standard stereotaxic space of the International Consortium for Brain Mapping. Voxel-based parametric images of raclopride C 11 binding were generated with the same reference region as for the ROI approach. Spatially normalized parametric images were smoothed with an isotropic gaussian kernel (fullwidth half-maximum of 14 mm for all directions).
STATISTICAL ANALYSIS
The main clinical characteristics of both groups of patients were compared using the Mann-Whitney nonparametric test, with significance at PϽ.05.
The mean raclopride C 11 binding values of on-drug PD patients were compared with those of off-drug PD patients and with those of controls using a 1-way analysis of variance. A post hoc analysis was performed using an unpaired 2-tailed t test with Bonferroni correction (PϽ.05).
In addition, categorical comparisons of mean raclopride C 11 voxel-based binding values between both groups of PD patients and controls were made, applying SPM. These analyses were limited to the striatal regions using an appropriate mask. Significant differences were localized using SPM, with residual df of 10 from 12 images. The contrasts were used to derive between-condition z scores on a voxel-by-voxel basis using the general linear model. 18 The P values were corrected for multiple comparisons implicit in SPM. In the voxel-based analysis, a corrected P value of less than.01 at the cluster level was considered significant. These voxels were localized using their coordinates in the Talairach and Tournoux brain atlas after having converted coordinates obtained from SPM software (SPM 99) in Talairach coordinates using the appropriate formula (to get from McGill [MNI]-SPM96 coordinates to Talairach 88-SPM95 coordinates: xЈ = 0.88x − 0.8; yЈ = 0.97y − 3.32; and zЈ=0.05y+0.88z-0.44). 19 
RESULTS
ROI ANALYSIS
In off-drug PD patients, the mean ± SD raclopride C 11 binding values in the off STN stimulation condition were 3.4 ± 0.5 and 2.1 ± 0.4 for the putamen and caudate nucleus, respectively.
In on-drug PD patients, the mean ± SD binding values in the off STN stimulation condition were 2.6±0.6 and 1.7±0.2 for the putamen and caudate nucleus, respectively.
In control subjects, the mean±SD binding values were 2.7 ± 0.3 and 2.2 ± 0.2 for the putamen and caudate nucleus, respectively.
An analysis of variance showed a highly statistically significant heterogeneity among groups for the caudate nucleus and putamen.
Off-Drug vs On-Drug PD Patients
A significant increase of raclopride C 11 binding was observed after dopaminergic drug withdrawal in the putamen (mean±SD, 3.4 ± 0.5 vs 2.6 ± 0.6; P=.03). The same trend was noted for the caudate nucleus (2.1 ± 0.4 vs 1.7±0.2), but did not reach statistical significance (P=.07).
PD Patients vs Controls
No difference in putamen raclopride C 11 binding was noted between control subjects and on-drug patients, while raclopride C 11 binding was higher in off-drug patients compared with on-drug patients and controls (P=.03). Ondrug PD patients had lower caudate nucleus raclopride C 11 binding than did controls (P=.04), whereas no significant difference was noted between controls and offdrug patients. These results are presented in the Figure. 
SPM ANALYSIS
Raclopride C 11 binding values were higher, at the cluster level, bilaterally in the putamen but also in the caudate nucleus in the off-drug compared with the on-drug patients. Other results are similar to those obtained with the ROI analysis, and are presented in Table 2 .
COMMENT
The present study demonstrates that, in advanced PD patients undergoing long-term STN stimulation, only those requiring dopaminergic treatment have a reduced striatal raclopride C 11 binding compared with controls. In contrast, patients not receiving antiparkinsonian medication displayed an increased raclopride C 11 putaminal binding.
Both methods of analysis provided the same results, except for the caudate nucleus, for which the ROI analysis did not show any significant difference of raclopride C 11 binding between on-and off-drug patients, whereas the SPM analysis demonstrated a higher raclopride C 11 binding for the caudate and the putamen in off-drug patients. This may represent a higher sensitivity of this method of analysis, which is voxel based.
In advanced on-drug PD patients, the reduced raclopride C 11 binding in the caudate nucleus is in keeping with the results of most PET studies and with postmor- In the putamen, no difference in raclopride C 11 binding was noted between control subjects and on-drug Parkinson disease (PD) patients, while raclopride C 11 binding was higher in off-drug PD patients compared with on-drug PD patients and controls (P = .03). In the caudate nucleus, on-drug PD patients had lower raclopride C 11 binding than did controls (P=.04) while no significant difference was noted between controls and off-drug PD patients (P = .3).
(REPRINTED) ARCH NEUROL / VOL 61, NOV 2004 tem histological studies that reported normal or reduced striatal dopamine D 2 receptor density. 3, 7, 8, [20] [21] [22] [23] However, is this a consequence of the long-term dopaminergic treatment or of PD progression? Trying to answer this question is complex because the usual 12-hour antiparkinsonian drug withdrawal before PET data acquisition does not prevent direct competition for receptor binding between dopamine, long half-lived dopamine agonists, and raclopride C 11. 3, 7, 8, 10, 11 Thus, differentiating a direct competition effect from a progressive drug-induced modification of dopamine D 2 receptor expression is difficult. In our study, taking advantage of the possibility, after STN stimulation, to discontinue dopaminergic drugs in some PD patients, we addressed the question of the long-term changes of dopamine receptors induced by dopaminergic drugs by studying the modifications of dopamine D 2 receptors after prolonged medication withdrawal. Our results support a direct effect of long-term and intermittent dopaminergic drug administration on dopaminergic D 2 receptor expression and show that these effects are reversible after medication withdrawal. Indeed, the down-regulation of dopamine D 2 receptors disappeared in patients in whom medications were withdrawn for months. This down-regulation may be mediated by an internalization of dopamine D 1 /D 2 receptors, making ligands unable to access their targets. 24 Furthermore, in our unmedicated advanced PD patients, the putaminal raclopride C 11 binding was significantly higher than in healthy subjects. Such upregulation of putaminal dopamine D 2 receptors has only been observed in de novo drug-naive PD patients. This is usually interpreted as a compensatory mechanism. [2] [3] [4] [5] [6] [7] [8] [9] Reduced receptor competition secondary to the reduction of endogenous dopamine release in PD has also been suspected, but the compensatory hypothesis has been supported by studies using a combination of reversible (raclopride C 11) and irreversible (methyl-spiperone labeled with C 11) dopamine receptor ligands. 9 Our data suggest that this compensatory up-regulation persists in ad-vanced PD patients in the absence of dopaminergic treatment. This fits well with histological data showing that supersensitivity of dopaminergic D 2 receptors occurs when 80% or more of the nigrostriatal neurons are destroyed in monkeys or rats treated with N-methyl-4-phenyl-1,2,3,6tetrahydropyridine or 6-hydroxy-dopamine and in humans with advanced PD. 25, 26 In monkeys treated with N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine, this increase of dopamine D 2 receptor binding has been demonstrated in the putamen and the caudate. 26 In the present study, we did not observe such up-regulation in the caudate. However, our data clearly showed, for the putamen and the caudate, an increase of raclopride C 11 binding, but from a normal to an increased level for the putamen and from a down-regulated to a normal level for the caudate. This further supports the role of dopaminergic medications, which equally down-regulate dopamine D 2 receptors in both elements of the striatum.
Finally, our results cannot be explained by differences in the clinical characteristics of our 2 groups because their disease duration, age, preoperative levodopa responsiveness, time to PET scanning after STN surgery, and motor complication improvement after STN stimulation were similar. The reasons that led one group to complete drug withdrawal while the other still required medication are, therefore, probably more related to the stimulation itself (eg, electrode placement) or to more severe disability and to nondopaminergic characteristics of our on-drug PD patients, as suggested by the higher UPDRS motor score at the time of the PET scan. It could be hypothesized, therefore, that STN stimulation itself may have differently affected the striatal raclopride C 11 binding in the 2 groups. However, this seems improbable for the following reasons: (1) the stimulation variables were identical in both groups of patients;
(2) at the time of the studies, the stimulators were switched off for 1 hour; and (3) STN stimulation has no shortterm effect on striatal raclopride C 11 binding. 15 It seems, therefore, most probable that the difference reflects the effects of the antiparkinsonian medication on dopamine D 2 receptor regulation.
In conclusion, our study suggests the following: (1) The dopaminergic D 2 receptor down-regulation in late-stage PD is mainly secondary to antiparkinsonian medication and could be reversible after long-term drug withdrawal. Future longitudinal prospective studies of the striatal raclopride C 11 binding changes before and prospectively after STN surgery would be necessary to confirm and precisely delineate the timing of the normalization of dopamine D 2 receptor expression, and (2) In off-drug late-stage PD patients, an up-regulation of dopaminergic D 2 receptors is observed, in keeping with postmortem histological observations in those with severe dopaminergic lesions.
